How To
Meet Biocompatibility Needs Of Polymeric Medical
Components
The steps involved the selection of materials and their
evaluation and testing is as follows:
1. Risk Assessment
The intended use and application of the final device is
first identified. The initial design concepts can be used
to conduct an initial risk assessment of the device
design, the material and component characteristics, the
manufacturing processes including sterilization, the
clinical use of the device, and the nature and duration of
contact with human tissue.
The nature of contact falls into three categories per
the standard.
• Surface contacting devices – Those devices contacting
skin, mucosal membranes or breached and compromised
surfaces (broken skin)
• External contacting devices – Those devices that contact
blood paths indirectly, tissue/bone/dentin and circulating
devices
• Implantable devices – Those devices that come into long
term contact with tissue and bone, and blood
The durations of contact are:
• Limited Exposure – Contact up to 24 hours
• Prolonged exposure - Contact between 24 hours and <29
days
• Permanent contact – Contact e” 30 days
This information should be used to identify potential
risks with respect to biocompatibility and the types of
biocompatibility tests that need to be conducted. The
standard and the guidance document allow for the use of
historical data and information to make informed decisions
before committing to extensive biocompatibility
testing..
2. Identification of Potential Risks and Exposure
Assessment
The physical and chemical characteristic of the materials
under evaluation should be listed. Before conducting any
biocompatibility tests the potential risks can be
evaluated using methods like literature and historical
data. Sources of information on potential biocompatibility
risks can include previous experience with the same
material(s) that have been used in the same or similar
devices in the same anatomical location. In addition post
market data for similar devices and applications can
also provide a rich source of data as an initial risk
assessment for biocompatibility.
3. Material selection
When selecting materials to be used in a specific device
design, manufacture and use, consideration should be given
to the fitness for the device’s intended use with respect
to chemical, toxicological, physical, electrical,
morphological and mechanical properties. With respect to
the biological evaluation of the device, the
following should be considered:
i. The properties of the base resin
The choice of the base resin can be constrained by the
application and process needs of the device. For example,
hydrolytically unstable resins cannot be used in implants.
Highly porous materials may not be suitable under ethylene
oxide sterilization because unremoved residuals from
ethylene oxide could impact patient safety. Thermally
unstable grades cannot be used in applications where high
temperature autoclave sterilization is required. In
addition to physical and mechanical
instability, degradation products could affect the
material’s biocompatibility.
ii. The material formulation
Additives, catalysts, colorants, fillers, nanoparticles,
plasticizers and other materials either alone or by
interactions with each other can significantly affect
biocompatibility. If each individual component of the
formulation is claimed to be biocompatible, it does not
automatically mean that the complete, formulated material
is biocompatible. Compounders should evaluate the breadth
of additives and a range of levels in their formulations
to gain maximum flexibility of biocompatible materials in
their portfolio.
iii. Manufacturing Processes – Degradation and Residues
Excessive heat and shear during the manufacturing of
plastic parts can change the levels of extractables and
leachables in the final part and thus significantly affect
biocompatibility. Joining and cleaning of parts and
residues from materials used in facilitating production
(e.g. mold release) can also change a product’s biological
properties. Processors should define the process ranges
that will not affect biocompatibility.
iv. Master Files
In the case where formulations are proprietary, Device
Master Files (MAF) of the product can be used. Material
suppliers can submit a Device Master File that is privy
only to the FDA for review and evaluation of final device
submissions. Device Master Files typically contain the
name of the product, its formulation (ingredients and
levels), manufacturing conditions, sterilization
compatibility, physical and mechanical properties, known
impurities and chemical characterization. Included are
also biocompatibility screening studies.
4. Biological Evaluation
In order to reduce unnecessary testing, including animal
testing, manufacturers should first consider all available
relevant information from literature and test data For
example, in some circumstances, a chemical analysis can
demonstrate that the extractables and leachables using a
specific solvent have not changed compared to a baseline
material, eliminating the need for additional
biocompatibility testing using that type of solvent. In
addition, chemical analyses can be used to assess the
toxicological risk of the chemicals that elute from
devices. For example, chemical analysis using exhaustive
extraction techniques can also be helpful to evaluate
long-term toxicity endpoints such as potential
carcinogens.
Page
1 :
2 :
3 |